


Endometrial Cancer Prognostication Panel

Next Generation Sequencing based genomic profiling for molecular classification of endometrium cancer



ESGO–ESMO–ESTRO risk stratification model classifies endometrial cancer into four subgroups according to molecular profile.



MedGenome Endometrial Cancer Prognostication Gene Panel

Genomic alterations in 32 endometrial cancer related genes are screened along with mutations in **POLE**, **TP53**, **MMR** genes using NGS

- Provides accurate diagnosis, prognosis and therapy selection for all stages of disease etiology including recurrent disease
- Provides information on genes which might be involved in germline origin of disease such as **BRCA1**, **BRCA2** and **MMR** pathway genes.
- Covers tumour agnostic biomarkers such **BRAF**, **RET**, **NTRK1**, **NTRK2** and **NTRK3** which have approved targeted therapies across all metastatic solid tumours.

Laboratory developed assay
as per CAP guidelines

Sensitivity >98% and
Specificity with 100%

Limit of detection:

- 5% VAF for SNV and InDels,
- >10 Spanning Reads for Fusions,
- >2.5-fold Change for CNV

Benefits



Molecular subgrouping allows better prediction of prognosis.



Tailoring different treatment modalities such as surgery, pelvic radiotherapy, vaginal brachytherapy, chemotherapy and immunotherapy.*

*Crosbie, Emma J., et al. "Endometrial cancer." The Lancet 399.10333 (2022): 1412-1428.

Test Details

Test Code	TAT	Test Name	Inclusions
MGM1434	21 Working Days	Endometrial Cancer - POLE gene sequencing	POLE by NGS
MGM3239	14 Working Days	Endometrial Cancer - Basic NGS Panel	POLE, TP53, MLH1, MSH2, MSH6, PMS2 by NGS
MGM3240	14 Working Days	Endometrial Cancer - Molecular Classification Panel	POLE by NGS + TP53 by IHC + dMMR by IHC
MGM2581	14 Working Days	Endometrial Cancer panel by NGS	As shown in the Gene List Below

Methodology: Next Generation Sequencing | Specimen Type: FFPE Tissue Block / Tissue in RNAlater

Gene List (MGM2581)

GENES	SNVs/ InDels	FUSION	GENES	SNVs/ InDels	FUSION	GENES	SNVs/ InDels	FUSION
AKT1	Y	N	FGFR2	Y	Y	PIK3CA	Y	N
ARID1A	Y	N	FGFR3	Y	Y	PIK3R1	Y	N
BRCA1	Y	N	KRAS	Y	N	PMS2	Y	N
BRCA2	Y	N	MLH1	Y	N	POLD1	Y	N
BRAF	Y	N	MSH2	Y	N	POLE	Y	N
CHEK2	Y	N	MSH3	Y	N	PTEN	Y	N
CTNNB1	Y	N	MSH6	Y	N	RET	Y	Y
EPCAM	Y	N	MUTYH	Y	N	SMARCA4	Y	N
ERBB2	Y	N	NTRK1	Y	Y	STK11	Y	N
FBXW7	Y	N	NTRK2	Y	Y	TP53	Y	N
FGFR1	Y	Y	NTRK3	Y	Y			

*Tumor Cellularity can not be determined for tissue in RNA later samples. VAF : Variant Allele Frequency

*RNAlater solution will be provided by MedGenome

Talk to the Experts:

1800 103 3691

diagnostics@medgenome.com

www.medgenome.com

Scan to
Follow us on
LinkedIn

